Covid19 - Christine Cotton : "La science ce n'est pas de la politique, c'est de la statistique !"

Key statements

• Developing a drug normally takes 10 to 15 years. Between China sequencing SARS-CoV-2 in March 2020 and the Pfizer vaccine reaching the market, nine months elapsed. Phase 2 began before Phase 1 was complete; Phase 3 began before Phase 2 was complete — unprecedented. ▶ 06:15
  Sources: Pfizer C4591001 Protocol
• What the 95% efficacy actually covered: only PCR-confirmed mild or moderate COVID cases. The December 2020 report shows no demonstrated efficacy on severe cases and no demonstrated efficacy in the 75+ subgroup. ▶ 10:21
  Sources: Pfizer C4591001 interim clinical study report (Dec 2020)
• Despite the report showing no efficacy on severe cases or the 75+, the public discourse was that everyone had to be vaccinated, starting with the elderly. The same flawed three-month interim with half the participants followed for less than two months was reproduced for the 12-15, 5-11 and infant cohorts. ▶ 10:50
  Sources: Pfizer C4591001 interim clinical study report (Dec 2020); Pfizer pediatric trial reports (12-15, 5-11, 6 months-4 years)
• Pregnant women are always excluded from clinical trials as a protected population. Pfizer's pregnancy-specific trial ended in July 2022 with no released results. Cotton: "We have no clinical trial results for the populations I just listed" — pregnant women, immunocompromised, comorbidities. ▶ 11:47
  Sources: Pfizer pregnancy clinical trial (terminated July 2022, no results released)
• Science is not politics — it is statistics. Cotton attributes the political polarization around COVID vaccines to harassment networks on social media tied to TV doctors, journalists, and politicians. ▶ 13:47
• Using the FDA-released trial database and recomputing efficacy on the anti-nucleocapsid serology criterion (which captures actual SARS-CoV-2 infection regardless of symptoms), efficacy is around 55% — not 95%. The result is dependent on the chosen endpoint, and this 55% number was never presented in the clinical reports. ▶ 16:25
  Sources: Pfizer C4591001 trial database (FOIA / court-released)
• EMA's monovalent Pfizer adverse-event reports stand at 1.2 million, and Cotton estimates a 10× or higher under-reporting factor. The narrative push to declare the vaccine subject "old news" is a way of trying to escape responsibility. ▶ 19:21
  Sources: EudraVigilance (EMA adverse-event database)
• Cotton's January 2022 expertise calls for a temporary suspension and an audit of how the trial was actually conducted on the ground. The more the FOIA'd databases come out, the more discrepancies appear. ▶ 21:06
  Sources: Cotton — Expertise of the Pfizer C4591001 trial (January 2022)
• States signed procurement contracts that exonerate the labs from liability. If trials are not reliable, the contracts should be revisited and the labs forced to pay — there is no reason for taxpayers to fund adverse-event compensation on the basis of trials that are inadmissible. ▶ 21:50
  Sources: EU Advance Purchase Agreements (Pfizer/BioNTech)
• Two days after Cotton posted her report on LinkedIn, her profile was visited by the WHO, US State Department, Apple, the French Interior Ministry, the Ministry of the Armed Forces, the Gendarmerie Nationale — "not the people you debate with." ▶ 29:20
  Sources: Cotton — January 2022 expertise report (LinkedIn post)

Documents cited

• Pfizer C4591001 Protocol — NEJM supplementary materials
• Pfizer C4591001 interim clinical study report (December 2020) — FDA briefing documents, Dec 2020 VRBPAC
• Pfizer pediatric trial reports (12-15, 5-11, 6 months-4 years) — FDA / EMA submissions
• Pfizer pregnancy clinical trial (terminated July 2022, no results released) — ClinicalTrials.gov record (NCT04754594)
• Pfizer C4591001 trial database (court-released) — Court orders following FOIA / PHMPT litigation
• EudraVigilance (EMA) — adverse-event database — adrreports.eu
• EU Advance Purchase Agreements (Pfizer/BioNTech) — European Ombudsman OI/4/2022/PB
• HAS (Haute Autorité de Santé) — 2 February 2021 opinion on AstraZeneca AZD1222 — has-sante.fr
• Cotton — Expertise of the Pfizer C4591001 trial (January 2022) — christinecotton.com

• Reproduce Cotton's 55% recalculation: pull the court-released Pfizer C4591001 trial database, run the analysis on the anti-nucleocapsid serology endpoint, and archive the script + result. This would give the archive an independently reproducible exhibit for the case-definition argument.Cited at 16:25 as the smoking-gun statistic that the 95% headline was driven by the choice of endpoint.

  Sources she cites in the book

  • Pfizer C4591001 trial database / SAS dataset made publicly available by attorney Aaron Siri (ICAN/Siri & Glimstad, via court-released FDA documents)
  • 150 OpenVAET (Substack) — 'Pfizer/BioNTech C4591001 Trial Audit'
  • 149 WHO — Technical briefing (April 2021), 'Regulation of COVID-19 vaccines' synopsis Aug 2020–Feb 2021 ⧉ archived
• Locate the ClinicalTrials.gov record for the Pfizer-BioNTech pregnancy trial that ended in July 2022, and document whether any results have since been posted. Cotton states (~12:00) no results were released.Critical follow-up: an unpublished pregnancy trial undermines official agency assurances that there is "no signal" in pregnant women.

  Sources she cites in the book

  • 252 ClinicalTrials.gov — record NCT04754594 (Pfizer/BioNTech BNT162b2 study in pregnant women)
  • 253 ClinicalTrials.gov (Provided Docs) — NCT04754594 study protocol, final version dated 5 March 2022
  • ClinicalTrials.gov — NCT04754594 results/version history (version 24)
• Capture the HAS opinion of 2 February 2021 on AstraZeneca AZD1222 (the quote Bercoff reads at ~15:17): "data do not allow conclusion on vaccine efficacy in those aged 65 and over, severe forms, or asymptomatic forms."A French regulator stating publicly that the data did not support efficacy on the elderly or severe forms — a citable counterweight to the 95% messaging.

  Sources she cites in the book

  • 30 FDA — VRBPAC meeting (10 Dec 2020), Pfizer/BioNTech BNT162b2 sponsor presentation by William Gruber
  • 31 VIDAL (vidal.fr), archived 25 Feb 2021 via the Wayback Machine — COMIRNATY vaccine page
  • 32 VIDAL (vidal.fr), archived 25 Feb 2021 via the Wayback Machine — COMIRNATY vaccine page (citation for the quoted text)
• Catalog the call-in segments with listeners (Emilien, a suspended firefighter; Christophe of Angers) — both are anecdotal but valuable as voiced testimony of the vaccine-mandate cohort. Add to the trial-injuries / mandate documentation track.Both callers (~24:00 and ~26:08) ground the abstract critique in the lived experience of mandated French professionals.